Examining the Details of the Recent Updates to MS-DRGs

As we near the end of what some consider the most unprecedented year in coding, there are more updates to review and decipher in preparation for 2021.  

As the science around the COVID-19 pandemic continues to evolve, there remain many unknowns of post-COVID-related conditions. There is an ongoing and urgent need to capture more information about the disease by the global healthcare community.

The Centers for Disease Control and Prevention (CDC), under the National Emergencies Act Section 201 and 301, announced further additions to ICD-10-CM classification related to COVID-19. Additionally, the Centers for Medicare & Medicaid Services (CMS) has posted new guidelines for ICD-10 CM/PCS coding and an updated MS-DRGs, Version 38.1 ─ all effective Jan. 1, 2021. Updates include new ICD-10-CM and PCS codes for COVID-19.

ICD-10 MS-DRGs, Version 38.1 

The ICD-10 MS-DRG grouper software package to accommodate these new codes, Version 38.1, is effective for discharges on or after Jan. 1, 2021.

The six new diagnosis codes proposed are:

  • 82, Pneumonia due to coronavirus disease 2019
  • 81, Multisystem inflammatory syndrome
  • 89, Other specified systemic involvement of connective tissue
  • 52, Encounter for screening for COVID-19
  • 822, Contact with and (suspected) exposure to COVID-19
  • 16, Personal history of COVID-19

The new diagnosis codes were proposed and discussed in detail at the September 2020 ICD-10 Coordination and Maintenance Committee (C&M) meeting. The CDC announcement, along with the new codes and their MS-DRG assignment, is available as a one-page PDF on the CMS website, and the Index and Tabular Addenda for the new codes will be posted on the CDC’s ICD-10 CM page.

COVID-19 Therapeutics and Vaccines

In addition to new ICD-10-PCS codes for the administration of remdesivir and transfusion of convalescent plasma (implemented earlier this year and effective Aug. 1, 2020), the 21 new PCS codes (effective Jan. 1, 2021) include codes to capture the use of additional COVID-19 therapeutics, as well as administration of COVID-19 vaccines.

All of these new PCS codes are classified in table XW0 of the ICD-10-PCS. The codes specify the substance name or type and administration route – whether by subcutaneous/intramuscular injection, IV infusion, or oral administration.

Monoclonal Antibody (10 codes)

Four specific substances classified as monoclonal antibodies – Bamlanivimab, Etesevimab, Leronlimab, and REGN-COV2 – have new PCS codes to track their use in treating COVID-19. Leronlimab is administered by subcutaneous injection, and the other three substances are administered via IV infusion.

  • XW013K6, Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW043E6, Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW033E6, Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033F6, Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW043F6, Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW033G6, Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW043G6, Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Three non-specific monoclonal antibody codes were added to allow tracking of other monoclonal antibody drugs approved for the treatment of COVID-19 in the coming months:

  • XW033H6, Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW043H6, Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW013H6, Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

Other Drug Class (5 codes)

Two specific substances – the drug baracitinib (trade name Olumiant®) and an immunomodulator drug known as CD24Fc – also have new codes for tracking their use as COVID-19 therapies. Baracitinib recently received Food and Drug Administration (FDA) emergency use authorization (EUA) as a treatment for COVID-19, in combination with remdesivir. Baracitinib can be administered orally or via gastrostomy/jejunostomy tube. The immunomodulator substance designated CD24Fc is administered via IV infusion.

  • XW0DXM6, Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
  • XW0G7M6, Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6
  • XW0H7M6, Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6
  • XW043L6, Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW033L6, Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6

Vaccine (6 codes)

Six new PCS codes were added for tracking COVID-19 vaccination while a patient is in the hospital. Likely, the vast majority of vaccines will not be administered to patients while they are in the hospital; nevertheless, these PCS codes will allow for the applicable data to be captured on an inpatient record.

The new PCS codes specify whether the vaccine was a subcutaneous or intramuscular injection, and whether the injection was the first dose or the second, for vaccines that require two injections to complete the therapy. The codes that do not specify dose are to be used for single-dose vaccinations, or when information regarding the dose is not available in the medical record.

  • XW013S6, Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013T6, Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013U6, Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW023S6, Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023T6, Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023U6, Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6

For MS-DRGs, the new PCS codes are designated Non-OR and will not affect DRG assignment. However, CMS noted in their official announcement, “for hospitalized patients; Medicare pays for the COVID-19 vaccines and their administration separately from the Diagnosis-Related Group rate. As such, Medicare expects that the appropriate CPT codes will be used when a Medicare beneficiary is administered a vaccine while a hospital inpatient.”

 

The CMS announcement, which contains the list of 21 PCS codes, can be accessed on the CMS website here: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software

The Index and Tabular Addenda for the new codes can be found on the CDC’s ICD-10-CM page: https://www.cdc.gov/nchs/icd/icd10cm.htm

Programming Note: Listen to Susan Gatehouse report this story live today during Talk Ten Tuesdays, 10 a.m. EST.

Print Friendly, PDF & Email
Facebook
Twitter
LinkedIn

Susan Gatehouse, RHIT, CCS,CPC, AHIMA-Approved ICD-10-CM/PCS Trainer

Susan Gatehouse is the founder and chief executive officer of Axea Solutions. An industry expert in revenue cycle management, Gatehouse established Axea Solutions in 1998, and currently partners with healthcare organizations across the nation, to craft solutions for unique challenges in the dynamic world of healthcare reimbursement and data management.

Related Stories

How to Report New Code Category W44

How to Report New Code Category W44

One of the goals of medical coding is documenting encounter notes to the highest degree of specificity. ICD-10-CM had some existing codes for documenting foreign

Read More

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

Leveraging the CERT: A New Coding and Billing Risk Assessment Plan

Leveraging the CERT: A New Coding and Billing Risk Assessment Plan

Frank Cohen shows you how to leverage the Comprehensive Error Rate Testing Program (CERT) to create your own internal coding and billing risk assessment plan, including granular identification of risk areas and prioritizing audit tasks and functions resulting in decreased claim submission errors, reduced risk of audit-related damages, and a smoother, more efficient reimbursement process from Medicare.

April 9, 2024
2024 Observation Services Billing: How to Get It Right

2024 Observation Services Billing: How to Get It Right

Dr. Ronald Hirsch presents an essential “A to Z” review of Observation, including proper use for Medicare, Medicare Advantage, and commercial payers. He addresses the correct use of Observation in medical patients and surgical patients, and how to deal with the billing of unnecessary Observation services, professional fee billing, and more.

March 21, 2024
Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets

Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets

Explore the top-10 federal audit targets for 2024 in our webcast, “Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets,” featuring Certified Compliance Officer Michael G. Calahan, PA, MBA. Gain insights and best practices to proactively address risks, enhance compliance, and ensure financial well-being for your healthcare facility or practice. Join us for a comprehensive guide to successfully navigating the federal audit landscape.

February 22, 2024
Mastering Healthcare Refunds: Navigating Compliance with Confidence

Mastering Healthcare Refunds: Navigating Compliance with Confidence

Join healthcare attorney David Glaser, as he debunks refund myths, clarifies compliance essentials, and empowers healthcare professionals to safeguard facility finances. Uncover the secrets behind when to refund and why it matters. Don’t miss this crucial insight into strategic refund management.

February 29, 2024
2024 ICD-10-CM/PCS Coding Clinic Update Webcast Series

2024 ICD-10-CM/PCS Coding Clinic Update Webcast Series

HIM coding expert, Kay Piper, RHIA, CDIP, CCS, reviews the guidance and updates coders and CDIs on important information in each of the AHA’s 2024 ICD-10-CM/PCS Quarterly Coding Clinics in easy-to-access on-demand webcasts, available shortly after each official publication.

April 15, 2024

Trending News

SPRING INTO SAVINGS! Get 21% OFF during our exclusive two-day sale starting 3/21/2024. Use SPRING24 at checkout to claim this offer. Click here to learn more →